Insulin glargine and lixisenatide - Biologic Drug Details

Summary for insulin glargine and lixisenatide

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for insulin glargine and lixisenatide

Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists
Established Pharmacologic Class	GLP-1 Receptor Agonist Insulin Analog
Chemical Structure	Glucagon-Like Peptide 1 Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin glargine and lixisenatide Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin glargine and lixisenatide Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	SOLIQUA 100/33	insulin glargine and lixisenatide	Injection	208673	10,413,622	2037-04-26	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	SOLIQUA 100/33	insulin glargine and lixisenatide	Injection	208673	10,653,733	2038-10-10	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	SOLIQUA 100/33	insulin glargine and lixisenatide	Injection	208673	10,744,212	2036-03-14	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	SOLIQUA 100/33	insulin glargine and lixisenatide	Injection	208673	10,744,213	2037-02-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin glargine and lixisenatide Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	SOLIQUA 100/33	insulin glargine and lixisenatide	Injection	208673	9,474,688	2032-10-25	Patent claims search
Sanofi-aventis U.s. Llc	SOLIQUA 100/33	insulin glargine and lixisenatide	Injection	208673	9,707,155	2034-04-23	Patent claims search

International Patents for insulin glargine and lixisenatide

Country	Patent Number	Estimated Expiration
Australia	2018316734
South Korea	101953011
Japan	2023076821
World Intellectual Property Organization (WIPO)	2019034887

Market Dynamics and Financial Trajectory for Insulin Glargine and Lixisenatide

Last updated: February 23, 2026

What are the current market positions of insulin glargine and lixisenatide?

Insulin glargine is a long-acting basal insulin used for type 1 and type 2 diabetes management. It generates approximately $4.5 billion annually in global sales, with Eli Lilly and Sanofi controlling most of the market. Lixisenatide, a GLP-1 receptor agonist marketed as Lyxumia and Adlyxin, generates roughly $250 million per year, mainly in Europe and select Asian markets.

How do market volumes and revenues compare for insulin glargine and lixisenatide?

Product	Estimated Global Sales (2022)	Primary Markets	Market Share (2022)	Annual Growth Rate (2022-2027)
Insulin glargine	$4.5 billion	US, Europe, Japan	55%	3-4%
Lixisenatide	$250 million	Europe, Japan, South Korea	4-6%	2-3%

Insulin glargine's dominant position stems from established formulary acceptance and extensive patient familiarity. Lixisenatide relies on expanded indications and combination therapies to increase market penetration.

What are the key market drivers and inhibitors?

Drivers:

• Growing prevalence of diabetes; projected to reach 700 million globally by 2045.
• Increased adoption of basal insulins due to efficacy and convenience.
• New formulations improving adherence, such as biosimilar insulin glargine.
• Intensified focus on reducing cardiovascular risk with GLP-1 receptor agonists.

Inhibitors:

• Price pressures from biosimilars for insulin glargine.
• Competition from biosimilar insulins and newer GLP-1 agents (e.g., semaglutide, tirzepatide).
• Variability in insurance coverage affecting patient access.
• Side effect profiles, including hypoglycemia risk with insulin and gastrointestinal effects with GLP-1s.

How are competitive developments shaping the landscape?

Biosimilar Entry

Sanofi launched Semglee (insulin glargine) biosimilar in 2021, with Walgreens and CVS offering it at a 25-30% discount. Eli Lilly's Basaglar, a similar biosimilar, maintains a significant share.

New Molecular Entities

Tirzepatide (Eli Lilly) combines GLP-1 and GIP receptor activity, demonstrating cardio-renoprotection and weight loss, with sales surpassing $300 million in 2022 and projected to reach $3 billion within five years.

Regulatory and Pipeline Trends

• Pfizer and Novo Nordisk develop long-acting insulins and next-generation GLP-1s.
• Multiple biosimilars of insulin glargine seek FDA approval, potentially eroding revenue.

What is the financial outlook for these drugs?

Insulin Glargine

• Revenue forecast to decline by 1-2% annually over the next five years due to biosimilar competition.
• Market share erosion expected to be offset temporarily by new delivery devices and contracts with healthcare providers.

Lixisenatide and Similar Agents

• Sales are expected to grow at 2-4% annually, driven by new indications and combination therapies.
• Price competition and nascent competition from oral GLP-1 formulations could impact growth.

Ancillary Revenue

Both drugs contribute to combination therapies, such as insulin GLP-1 receptor agonist co-formulations, which are garnering increasing prescriber interest. These formulations tend to command higher prices and higher margins.

What are the regulatory and reimbursement environments affecting revenue?

• US formulary coverage favors originator products, but biosimilar entry pressures prices.
• European systems favor price competition, leading to discounted reimbursement schemes.
• China's expanding healthcare coverage increases patient access but pressures pricing.
• Regulatory approvals for biosimilars and high-dose formulations influence market share shifts.

Key enterprise strategies:

• Sanofi and Lilly invest in biosimilars and combination formulations.
• Companies pursue early regulatory approvals in emerging markets.
• R&D focuses on faster-acting, longer-lasting, and more tolerable formulations.

Summary of potential investments and R&D focus areas:

• Biosimilar development and patent challenges.
• Next-generation GLP-1 molecules with improved efficacy and safety.
• Digital health integration with insulin delivery.
• Expansion into emerging markets driven by diabetes prevalence growth.

Key Takeaways

• Insulin glargine dominates with high revenue but faces biosimilar competition, leading to a gradual decline forecast.
• Lixisenatide remains a niche but growing segment, supported by innovation and expanding indications.
• Market growth hinges on diabetes prevalence, innovation, regulatory policy, and reimbursement strategies.
• Biosimilar entry and new therapeutics threaten to reshape revenue trajectories.
• Companies focusing on combination therapies and digital integration aim to sustain revenue streams.

FAQs

1. What factors will most influence insulin glargine's market share in the next five years?
   Biosimilar competition, pricing strategies, and formulary inclusion will drive market share dynamics.

2. How does lixisenatide compare to other GLP-1 receptor agonists?
   It has a shorter half-life and less market penetration but benefits from combination use and improved formulations.

3. Are biosimilars poised to significantly impact insulin glargine revenues?
   Yes; biosimilars have eroded prices by 20-30% and are expected to further reduce revenues.

4. What is the outlook for combination therapies involving insulin and GLP-1 agents?
   They are gaining favor due to improved patient adherence and clinical outcomes, supporting revenue growth.

5. Which emerging markets offer the greatest growth potential?
   China, India, and Southeast Asia demonstrate high growth potential due to rising diabetes prevalence and expanding healthcare coverage.

References

[1] International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th edition.
[2] EvaluatePharma. (2023). Diabetes therapeutics market analysis.
[3] U.S. Food & Drug Administration. (2022). Biosimilar approvals.
[4] IQVIA. (2022). Global Market Report: Diabetes Treatments.
[5] Sanofi. (2022). Annual Report 2022.